Vertex Pharmaceuticals could have several important catalysts this year. The stock's long-term outlook seems highly ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

RBC Capital Markets on Thursday upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Sector Perform, arguing that the ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

CHONGQING, CHINA - JULY 30: In this photo illustration, a smartphone displays the logo of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), a global biotechnology company focused on developing therapies for ...

Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- Enlaza Therapeutics (“Enlaza” or the “Company”), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with ...